子宫内膜癌的免疫耐受、代谢重编程及肿瘤微环境相关的分子机制探索

Molecular mechanisms implicated in immune tolerance, metabolic reprogramming, and the tumor microenvironment in endometrial cancer

同济大学附属妇产科医院青年联盟会长，团委委员

上海市医学会妇科肿瘤分会，委员

上海市医学会妇科肿瘤青委会，委员及秘书

上海市卵巢癌协作组成员

上海女医师协会妇儿专委会委员

上海市康复医学会第一届女性康复专委会委员

上海研究型医院学会妇产科转化医学研究与发展专业委员会第一届委员会委员

President of the Youth League at the Obstetrics and Gynecology Hospital affiliated with Tongji University and member of the Youth League Committee.

Member of the Gynecological Oncology Branch of the Shanghai Medical Association.

Member and Secretary of the Youth Committee on Gynecological Oncology within the Shanghai Medical Association.

Member of the Shanghai Ovarian Cancer Collaboration Group.

Member of the Women and Children Committee of the Shanghai Women's Physicians Association.

Member of the First Women's Rehabilitation Committee of the Shanghai Rehabilitation Medicine Association.

Member of the First Committee of the Obstetrics and Gynecology Translational Medicine Research and Development Committee, Shanghai Association of Research Hospitals.

美国梅奥医学中心访问学者、美国内布拉斯加医学中心访问学者。研究方向主要集中在子宫内膜癌的免疫分型、代谢特征和肿瘤微环境等方面，多次主持国家级和省市级科研项目，包括国家自然科学基金 3 项，上海市科委面上项目2项，申康三年行动计划临床研究课题 1 项，上海市科委——医学创新研究专项项目1项，总资助金额超过200万元。以第一/通讯作者发表SCI论文17篇，累计影响因子>150分，总引用次数为>1500次，并参编2022年卵巢恶性肿瘤诊疗上海专家共识，申请实用新型专利1项。

Dr. Li serves as a visiting scholar at the Mayo Clinic, USA, and has previously held a visiting scholar position at the Nebraska Medical Center, USA. Her research is centered on the immunophenotyping, metabolic characteristics, and tumor microenvironment of endometrial cancer. She has led numerous national, provincial, and municipal scientific research projects, including three funded by the National Natural Science Foundation, two general projects from the Shanghai Science and Technology Commission, one Shenkang Three-Year Action Plan Clinical Research Project, and one Shanghai Science and Technology Commission-Medical Innovation Research Special Project, with total funding exceeding 2 million yuan. She has authored 17 SCI papers as the first or corresponding author, achieving a cumulative impact factor greater than 150 and over 1,500 citations. She also contributed to the development of the 2022 Shanghai Expert Consensus on the Diagnosis and Treatment of Ovarian Malignant Tumors and has applied for one utility model patent.